IsoRay to Present at 9th Annual LD Micro Investor Conference

Nov 30, 2016

RICHLAND, Wash.Nov. 30, 2016 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that Tom LaVoy, Chairman and CEO, and Brien Ragle, CFO, will present a corporate overview at the 9th Annual LD Micro Main Event Investor Conference taking place on December 6-8, 2016 at the Luxe Sunset Boulevard Hotel, Los Angeles, CA.

Management will present on Tuesday, December 6, 2016 at 12:30pm PT. A live webcast of the presentation will be available at http://wsw.com/webcast/ldmicro11/isr. For those who are not available to listen to the live webcast, a replay will be archived on IsoRay’s website at https://isoray.com/about/investors/events-and-presentations/ for 90 days following the live event.

About IsoRay, Inc.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington Company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter @IsoRay.

Logo – http://photos.prnewswire.com/prnh/20160301/339505LOGO

Investor Relations:

Mark Levin

Global IR Group
(501) 255-1910

Media and Public Relations:

Sharon Schultz
Schultz Public Relations
(302) 539-3747
schultzpr@mchsi.com